Lineage Historical Financial Ratios
| LCTX Stock | USD 0.49 0.01 2.00% |
Lineage Cell is lately reporting on over 109 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 23.29 will help investors to properly organize and evaluate Lineage Cell Therapeutics financial condition quickly.
Lineage |
About Lineage Financial Ratios Analysis
Lineage Cell TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Lineage Cell investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Lineage financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Lineage Cell history.
Lineage Cell Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Lineage Cell Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Lineage Cell sales, a figure that is much harder to manipulate than other Lineage Cell Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Lineage Cell Therapeutics dividend as a percentage of Lineage Cell stock price. Lineage Cell Therapeutics dividend yield is a measure of Lineage Cell stock productivity, which can be interpreted as interest rate earned on an Lineage Cell investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Most ratios from Lineage Cell's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Lineage Cell Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lineage Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At this time, Lineage Cell's PTB Ratio is fairly stable compared to the past year. Book Value Per Share is likely to rise to 0.41 in 2025, whereas Price To Sales Ratio is likely to drop 10.06 in 2025.
| 2024 | 2025 (projected) | Dividend Yield | 0.001616 | 0.001535 | Price To Sales Ratio | 10.59 | 10.06 |
Lineage Cell fundamentals Correlations
Click cells to compare fundamentals
Lineage Cell Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lineage Cell fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 341.63 | 103.45 | 13.51 | 21.04 | 10.59 | 10.06 | |
| Ptb Ratio | 1.15 | 2.75 | 4.37 | 2.97 | 1.31 | 1.37 | |
| Days Sales Outstanding | 1.89 | 4.8K | 7.37 | 30.4 | 24.52 | 23.29 | |
| Book Value Per Share | 0.63 | 0.55 | 0.42 | 0.36 | 0.38 | 0.41 | |
| Free Cash Flow Yield | (0.25) | (0.075) | (0.0593) | 0.003252 | (0.23) | (0.24) | |
| Operating Cash Flow Per Share | (0.22) | (0.13) | (0.14) | 0.006237 | (0.17) | (0.12) | |
| Stock Based Compensation To Revenue | 2.88 | 0.9 | 0.29 | 0.52 | 0.53 | 0.51 | |
| Pb Ratio | 1.15 | 2.75 | 4.37 | 2.97 | 1.31 | 1.37 | |
| Ev To Sales | 303.74 | 89.86 | 13.0 | 17.41 | 6.03 | 5.73 | |
| Free Cash Flow Per Share | (0.27) | (0.22) | (0.13) | 0.003805 | (0.17) | (0.12) | |
| Roic | (0.2) | (0.25) | (0.34) | (0.22) | (0.27) | (0.21) | |
| Net Income Per Share | (0.14) | (0.23) | (0.16) | (0.12) | (0.093) | (0.0976) | |
| Payables Turnover | 0.13 | 0.17 | 0.15 | 0.3 | 0.33 | 0.28 | |
| Sales General And Administrative To Revenue | 20.14 | 4.67 | 1.53 | 1.93 | 1.91 | 1.82 | |
| Research And Ddevelopement To Revenue | 15.93 | 8.7 | 0.95 | 1.76 | 1.31 | 1.25 | |
| Capex To Revenue | 0.0828 | 0.0909 | 0.0281 | 0.0753 | 0.0678 | 0.0644 | |
| Pocfratio | (13.37) | (17.11) | 187.59 | (6.59) | (4.36) | (4.57) | |
| Capex To Operating Cash Flow | (0.00324) | (0.015) | 0.39 | (0.0236) | (0.0212) | (0.0223) | |
| Pfcf Ratio | (13.33) | (16.85) | 307.52 | (6.44) | (4.36) | (4.57) | |
| Days Payables Outstanding | 2.5K | 906.87 | 1.2K | 1.1K | 1.3K | 746.13 | |
| Income Quality | 0.95 | 0.54 | (0.0402) | 1.33 | 1.24 | 0.83 | |
| Roe | (0.22) | (0.42) | (0.36) | (0.34) | (0.24) | (0.23) | |
| Ev To Operating Cash Flow | (11.89) | (14.86) | 180.55 | (5.45) | (2.48) | (2.61) | |
| Pe Ratio | (12.77) | (10.45) | (7.54) | (8.76) | (5.41) | (5.68) | |
| Return On Tangible Assets | (0.18) | (0.41) | (0.33) | (0.4) | (0.49) | (0.35) | |
| Ev To Free Cash Flow | (11.85) | (14.64) | 295.97 | (5.33) | (2.48) | (2.61) | |
| Earnings Yield | (0.0783) | (0.0957) | (0.13) | (0.11) | (0.18) | (0.19) | |
| Intangibles To Total Assets | 0.53 | 0.33 | 0.46 | 0.57 | 0.51 | 0.44 | |
| Net Debt To E B I T D A | 1.2 | 1.1 | 0.34 | 1.35 | 2.01 | 2.12 | |
| Current Ratio | 5.66 | 2.37 | 3.16 | 2.14 | 3.65 | 5.31 | |
| Tangible Book Value Per Share | 0.25 | 0.2 | 0.0858 | 0.0277 | 0.0989 | 0.094 | |
| Receivables Turnover | 193.25 | 0.0766 | 49.51 | 12.01 | 14.89 | 16.3 | |
| Shareholders Equity Per Share | 0.78 | 0.64 | 0.56 | 0.43 | 0.37 | 0.38 | |
| Debt To Equity | 0.0458 | 0.0343 | 0.0304 | 0.0531 | 0.0465 | 0.0326 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.